| Primary |
| Asthma |
11.1% |
| Drug Level |
9.3% |
| Rhinitis Allergic |
8.3% |
| Routine Health Maintenance |
8.3% |
| Attention Deficit/hyperactivity Disorder |
5.6% |
| Gastric Ulcer |
5.6% |
| Gastrooesophageal Reflux Disease |
5.6% |
| Nausea |
5.6% |
| Primary Immunodeficiency Syndrome |
5.6% |
| Guillain-barre Syndrome |
4.6% |
| Depression |
3.7% |
| Dermatitis Contact |
3.7% |
| Hypertension |
3.7% |
| Anxiety |
2.8% |
| Decreased Appetite |
2.8% |
| Hypogammaglobulinaemia |
2.8% |
| Hypothyroidism |
2.8% |
| Insomnia |
2.8% |
| Migraine |
2.8% |
| Postmenopause |
2.8% |
|
| Haemolytic Anaemia |
30.3% |
| Renal Failure Acute |
12.1% |
| Tremor |
6.1% |
| Acquired Haemophilia |
3.0% |
| Asthenia |
3.0% |
| Circumstance Or Information Capable Of Leading To Medication Error |
3.0% |
| Death |
3.0% |
| Feeling Jittery |
3.0% |
| Incorrect Route Of Drug Administration |
3.0% |
| Infusion Related Reaction |
3.0% |
| Meningitis Aseptic |
3.0% |
| Optic Ischaemic Neuropathy |
3.0% |
| Pain |
3.0% |
| Pharyngeal Erythema |
3.0% |
| Photophobia |
3.0% |
| Product Counterfeit |
3.0% |
| Pulmonary Embolism |
3.0% |
| Renal Injury |
3.0% |
| Renal Tubular Necrosis |
3.0% |
| Respiratory Distress |
3.0% |
|
| Secondary |
| Product Used For Unknown Indication |
21.7% |
| Haematology Test Abnormal |
9.2% |
| Idiopathic Thrombocytopenic Purpura |
7.9% |
| Gastrooesophageal Reflux Prophylaxis |
7.1% |
| Immunosuppression |
7.1% |
| Bacteraemia |
6.9% |
| Antiemetic Supportive Care |
5.6% |
| Drug Level |
5.3% |
| Hypertension |
4.4% |
| Anaemia Haemolytic Autoimmune |
2.6% |
| Asthma |
2.5% |
| Autoimmune Thrombocytopenia |
2.5% |
| Drug Use For Unknown Indication |
2.5% |
| Transplant Rejection |
2.5% |
| Depression |
2.3% |
| Type 2 Diabetes Mellitus |
2.3% |
| Angioedema |
2.0% |
| Convulsion |
2.0% |
| Evans Syndrome |
2.0% |
| Kidney Transplant Rejection |
2.0% |
|
| Haemolytic Anaemia |
27.8% |
| Rectal Haemorrhage |
8.7% |
| Toxic Epidermal Necrolysis |
7.0% |
| Vaginal Haemorrhage |
6.1% |
| Drug Ineffective |
5.2% |
| Erythema Infectiosum |
5.2% |
| Pyrexia |
5.2% |
| Purpura |
4.3% |
| Rash Erythematous |
4.3% |
| Chronic Lymphocytic Leukaemia |
3.5% |
| Haemorrhage |
3.5% |
| Oligohydramnios |
3.5% |
| Death |
2.6% |
| Melaena |
2.6% |
| Blood Blister |
1.7% |
| Clostridium Difficile Colitis |
1.7% |
| Cytomegalovirus Infection |
1.7% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
1.7% |
| Haemoglobin Decreased |
1.7% |
| Progressive Multifocal Leukoencephalopathy |
1.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
22.3% |
| Idiopathic Thrombocytopenic Purpura |
11.0% |
| Prophylaxis |
10.4% |
| Prophylaxis Against Graft Versus Host Disease |
7.7% |
| Drug Use For Unknown Indication |
7.0% |
| Bone Marrow Conditioning Regimen |
6.1% |
| Nuclear Magnetic Resonance Imaging |
5.3% |
| Fistulogram |
3.9% |
| Infection Prophylaxis |
3.8% |
| Venogram |
3.6% |
| Multiple Myeloma |
3.1% |
| Antiviral Prophylaxis |
2.5% |
| Antibiotic Prophylaxis |
2.3% |
| Antifungal Prophylaxis |
1.8% |
| Hiv Test |
1.6% |
| Immunosuppression |
1.6% |
| Acute Lymphocytic Leukaemia |
1.5% |
| B Precursor Type Acute Leukaemia |
1.4% |
| Renal Transplant |
1.4% |
| Asthma |
1.4% |
|
| Death |
8.6% |
| Therapeutic Response Decreased |
8.6% |
| Chronic Graft Versus Host Disease |
7.5% |
| Platelet Count Decreased |
7.5% |
| Acute Graft Versus Host Disease |
6.9% |
| Anxiety |
5.7% |
| Drug Ineffective |
5.7% |
| Sepsis |
5.7% |
| Lung Neoplasm Malignant |
4.6% |
| Chronic Lymphocytic Leukaemia |
4.0% |
| Graft Versus Host Disease |
4.0% |
| Pneumocystis Jiroveci Pneumonia |
4.0% |
| Thrombocytopenia |
4.0% |
| Disease Progression |
3.4% |
| Joint Range Of Motion Decreased |
3.4% |
| Progressive Multifocal Leukoencephalopathy |
3.4% |
| Renal Failure |
3.4% |
| White Blood Cell Count Decreased |
3.4% |
| Cystitis Haemorrhagic |
2.9% |
| Febrile Neutropenia |
2.9% |
|
